Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis
- 13 September 2013
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 108 (6) , 387-397
Abstract
Background and Objectives To evaluate the predicting value of the epidermal growth factor receptor (EGFR) for survival in patients with head and neck cancer (HNC). Methods Data were collected from studies comparing overall survival (OS) or progression‐free survival (PFS) in patients with higher or lower EGFR levels. Studies were pooled and combined hazard ratios (HRs) of EGFR for survival were calculated. Results A total of 68 studies involving 6,781 patients were included for meta‐analysis. Either EGFR protein expression or gene copy number had prognostic value in HNC patients. EGFR overexpression could predict worse outcome, with HRs of 1.65 (95% CI: 1.45, 1.86) for OS and 1.27 (95% CI: 1.17, 1.37) for PFS. Increased EGFR copy number was also associated with reduced survival, with HRs of 1.5 (95% CI: 1.15, 1.96) for OS and 1.35 (95% CI: 1.14, 1.61) for PFS. Furthermore, EGFR overexpression could predict poorer OS in both eastern and western countries. Particularly, EGFR was considered a strong predictor in laryngeal squamous cell cancer (HR > 2). Conclusion Elevated EGFR expression and gene copy number could predict poor survival in HNC patients. J. Surg. Oncol. 2013; 108:387–397.Keywords
Funding Information
- National Natural Science Foundation of China (NSFC 30800401)
This publication has 77 references indexed in Scilit:
- Spinal metastasis in head and neck cancerHead & Neck Oncology, 2012
- Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell CarcinomaClinical Cancer Research, 2012
- New advances in molecular approaches to head and neck squamous cell carcinomaAnti-Cancer Drugs, 2011
- The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neckHead & Neck Oncology, 2011
- Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME studyAnnals of Oncology, 2010
- Integrating Epidermal Growth Factor Receptor Assay With Clinical Parameters Improves Risk Classification for Relapse and Survival in Head-and-Neck Squamous Cell CarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Expression modes and clinical manifestations of latent membrane protein 1, Ki‐67, cyclin‐B1, and epidermal growth factor receptor in nonendemic nasopharyngeal carcinomaHead & Neck, 2009
- Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor statusBritish Journal of Cancer, 2008
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001